Abstract: Macular edema (ME) is one of the eventual outcomes of various intraocular and systemic pathologies. The pathogenesis for ME is not yet entirely understood; however, some of the common risk factors for its development have been identified. While this investigation will not discuss the numerous etiologies of ME in detail, it appraises the two most widely studied delivery modalities of intraocular corticosteroids in the treatment of ME—intravitreal injection (IVI) and sub-Tenon’s infusion (STI). A thorough review of the medical literature was conducted to identify the efficacy and safety of IVI and STI, specifically for the administration of triamcinolone acetonide (TA), in the setting of ME in an attempt to elucidate a preferred steroid delivery modality for treatment of ME.
This is an open access article distributed under the
Creative Commons Attribution License which permits unrestricted use, distribution,
and reproduction in any medium, provided the original work is properly cited.
Export to BibTeX
MDPI and ACS Style
Pickrell, A.; Harris, A.; Ngo, S.; Amireskandari, A.; Stewart, E.; Siesky, B. Delivery of Intraocular Triamcinolone Acetonide in the Treatment of Macular Edema. Pharmaceutics 2012, 4, 230-242.
Pickrell A, Harris A, Ngo S, Amireskandari A, Stewart E, Siesky B. Delivery of Intraocular Triamcinolone Acetonide in the Treatment of Macular Edema. Pharmaceutics. 2012; 4(1):230-242.
Pickrell, Aaron; Harris, Alon; Ngo, Sandra; Amireskandari, Annahita; Stewart, Erin; Siesky, Brent. 2012. "Delivery of Intraocular Triamcinolone Acetonide in the Treatment of Macular Edema." Pharmaceutics 4, no. 1: 230-242.